Selected News

New data reinforce daratumumab as standard of care for multiple myeloma

April 15, 2025

Long-term survival projections suggest improved outcomes for patients New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet...

Global data highlights effectiveness of romosozumab

April 15, 2025

Studies show improved bone mineral density and healthcare cost reductions New data from multiple countries confirm the effectiveness of romosozumab,...

First treatment for common bladder cancer recommended by NICE

April 10, 2025

Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration Balversa (erdafitinib)...

Lab-grown lung cancer cells show potential to revolutionise treatment

April 10, 2025

The model could lead to more targeted treatments for the disease Cancer Research scientists have developed a new cell-based model...

NHS launches spring COVID-19 booster campaign

April 9, 2025

An estimated 7.5 million people will be invited to receive the booster The NHS has started delivering its spring COVID-19...

SkyCell and Microsoft partner to improve pharma supply chains

April 9, 2025

AI-powered SkyMind is designed to improve efficiency, compliance and decision-making SkyCell has partnered with Microsoft to launch SkyMind, an artificial...

MHRA approves prostate cancer imaging agent trofolastat

April 8, 2025

Approximately 55,100 new cases of prostate cancer are diagnosed every year in the UK The Medicines and Healthcare products Regulatory...

Endlyz Therapeutics emerges with pipeline for Parkinson’s disease

April 7, 2025

Research targets lysosomal function restoration for neurodegeneration Endlyz Therapeutics has launched from stealth, unveiling its pipeline of small molecule modulators...

SMC approves bimekizumab for hidradenitis suppurativa treatment

April 7, 2025

The Scottish Medicines Consortium (SMC) has approved bimekizumab for adults with active moderate to severe hidradenitis suppurativa (HS) who have...

European Commission approves ustekinumab for paediatric Crohn’s disease

April 3, 2025

Approval extends ustekinumab’s use to younger patients The European Commission (EC) has approved ustekinumab for the treatment of moderately to...

Elekta and Azra AI partner to advance cancer registry operations with AI

April 3, 2025

Collaboration introduces automation to enhance efficiency Elekta has announced a partnership with Azra AI to improve cancer registry workflows using...

4basebio receives MHRA licence for synthetic DNA manufacture

April 2, 2025

GMP certification enables 4basebio to supply DNA for clinical trials 4basebio PLC has been granted Good Manufacturing Practice (GMP) certification...

NICE recommends brentuximab vedotin plus AVD for Hodgkin lymphoma

April 2, 2025

Advancing care for stage 3 or 4 Hodgkin lymphoma patients The National Institute for Health and Care Excellence (NICE) has...

Diagnexia and Stratipath link up brings AI breast cancer diagnostics to UK

April 1, 2025

Collaboration expands AI-based risk profiling tools Diagnexia has announced a partnership with Stratipath AB to bring Stratipath Breast, an AI-based...

Genome editing offers hope for genetic hearing loss

March 27, 2025

New therapy developed to repair GJB2 R75W mutation Scientists from Juntendo University and The University of Tokyo have created an...

Amivantamab plus lazertinib shows survival benefit in lung cancer

March 27, 2025

Janssen drug combination extends life expectancy during trial Janssen-Cilag International NV has announced results from the phase 3 MARIPOSA study,...